BetterLife Pharma Inc (CSE:BETR) (OTCQB:BETRF) (FRA:NPAU), a company developing second-generation psychedelics for neuropsychiatric disorders, announced that former Food and Drug Administration (FDA) Psychiatry Division Director Thomas Laughren is joining the company as a regulatory advisor.
Laughren led the Division of Psychiatry Products and the Center for Drug Evaluation and Research at the FDA. He oversaw the review of all psychiatric drug development activities conducted under investigational new drugs (INDs) and the review of all new drug applications (NDAs) and supplements for new psychiatric drug claims, the company said.
He has authored and co-authored papers and book chapters on regulatory and methodological issues pertaining to psychiatric drugs, and he is a frequent speaker at professional meetings, the company added.
READ: Algernon Pharmaceuticals and Betterlife Pharma added to the world’s first psychedelic stock ETF
“We are thrilled to have Dr. Laughren join the company as regulatory advisor,” CEO Ahmad Doroudian said in a statement. “He brings invaluable psychiatric drug regulatory and development experience for our pipeline as we ramp up our IND-enabling activities.”
Betterlife’s therapeutic pipeline includes TD-0148A, a non-toxic second-generation lysergic acid diethylamide (LSD) derivative molecule that mimics the projected therapeutic potential of LSD in the treatment of disorders such as severe depression, substance dependencies, post-traumatic stress disorder (PTSD) and migraines.
Contact Andrew Kessel at email@example.com
Follow him on Twitter @andrew_kessel